Vident Investment Advisory’s Celyad Oncology SA American Depositary Shares CYAD Stock Holding History

Vident Investment Advisory’s Portfolio CYAD Stock Details CYAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	–	Sell	-21,872	Closed	-$966	–	395
2016 Q1	$966	Buy	21,872 +6,690	+44%	+$273K	0.06%	351
2015 Q4	$829K	Buy	+15,182	New	+$669K	0.1%	326

Other funds holding CYAD

RIM

RS Investment Management San Francisco, California $9.73B AUM 3.24% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Zurich Cantonal Bank Zurich, Switzerland $46B AUM 27.59% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Vident Investment Advisory's CYAD Position: Q2 2016 in Review

Vident Investment Advisory sold out of Celyad Oncology SA American Depositary Shares (CYAD) in Q2 2016, closing a stake of 21,872 shares — an estimated $966 sold.

Vident Investment Advisory first reported a position in CYAD in Q4 2015 and held it in 2 quarters. The position peaked at $829K in Q4 2015. 6 funds tracked by Wall St. Rank hold CYAD as of Q2 2016.

Vident Investment Advisory reported no remaining Celyad Oncology SA American Depositary Shares position as of Q2 2016 after selling out during the quarter.
Vident Investment Advisory sold 21,872 Celyad Oncology SA American Depositary Shares shares in Q2 2016, an estimated $966.
Vident Investment Advisory first reported a position in Celyad Oncology SA American Depositary Shares in Q4 2015 and held it in 2 quarters.
Vident Investment Advisory's Celyad Oncology SA American Depositary Shares position peaked at $829K in Q4 2015.
6 funds tracked by Wall St. Rank held Celyad Oncology SA American Depositary Shares as of Q2 2016.

Based on Vident Investment Advisory's 13F filing for Q2 2016, filed 12 Aug 2016.